Sinopharm Group (OTCMKTS:SHTDF – Get Free Report) is anticipated to announce its results before the market opens on Friday, August 21st. Analysts expect the company to post earnings of $0.1604 per share and revenue of $41.9439 billion for the quarter.
Sinopharm Group Stock Performance
Shares of OTCMKTS SHTDF opened at $2.13 on Thursday. The stock’s fifty day simple moving average is $2.16 and its 200 day simple moving average is $2.38. Sinopharm Group has a 52-week low of $2.11 and a 52-week high of $2.70.
Sinopharm Group Company Profile
Sinopharm Group Co, Ltd is one of China’s largest state-owned integrated healthcare companies, primarily focused on the research, development, production and distribution of a broad range of pharmaceutical and healthcare products. Established in 1998 through the reorganization of assets under China National Pharmaceutical Group (Sinopharm), the company has grown to encompass multiple business segments, including prescription medicines, over-the-counter drugs, vaccines and medical devices. Sinopharm Group is listed on the Hong Kong Stock Exchange and trades in the United States through its OTCMKTS ticker SHTDF.
The company’s product portfolio spans chemically synthesized drugs, biologics and traditional Chinese medicine formulations, supported by an extensive nationwide manufacturing and quality-control network.
Featured Stories
- Five stocks we like better than Sinopharm Group
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
